HS
VRDN icon

HighVista Strategies’s Viridian Therapeutics VRDN Stock Holding History

HighVista Strategies’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Buy
159,885
+25,656
+19% +$413K 0.67% 48
2026
Q1 		$2.63M Sell
134,229
-238,243
-64% -$7.08M 0.73% 46
2025
Q4 		$11.6M Sell
372,472
-96,863
-21% -$2.66M 2.99% 4
2025
Q3 		$10.1M Sell
469,335
-15,224
-3% -$275K 2.48% 4
2025
Q2 		$6.77M Buy
484,559
+304,008
+168% +$4.13M 2.49% 2
2025
Q1 		$2.43M Buy
180,551
+25,988
+17% +$443K 0.94% 21
2024
Q4 		$2.96M Sell
154,563
-30,677
-17% -$667K 1.1% 22
2024
Q3 		$4.21M Sell
185,240
-13,244
-7% -$217K 1.45% 9
2024
Q2 		$2.58M Hold
198,484
– – 0.94% 30
2024
Q1 		$3.48M Hold
198,484
– – 1.24% 23
2023
Q4 		$4.32M Buy
198,484
+93,728
+89% +$1.48M 1.57% 8
2023
Q3 		$1.61M Sell
104,756
-4,009
-4% -$76.5K 0.74% 41
2023
Q2 		$2.59M Buy
108,765
+13,856
+15% +$355K 1.18% 25
2023
Q1 		$2.41M Sell
94,909
-5,073
-5% -$163K 1.97% 17
2022
Q4 		$2.92M Sell
99,982
-2,390
-2% -$55.1K 1.73% 14
2022
Q3 		$2.1M Buy
102,372
+57,333
+127% +$1.03M 1.2% 28
2022
Q2 		$521K Sell
45,039
-4,026
-8% -$54.1K 0.31% 75
2022
Q1 		$907K Buy
+49,065
New +$943K 0.58% 43

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

HighVista Strategies's VRDN Position: Q2 2026 in Review

HighVista Strategies increased its Viridian Therapeutics (VRDN) stake by 19% in Q2 2026, buying an estimated $413K and bringing the position to 159,885 shares worth $2.94M. The position accounts for 0.67% of the portfolio, ranked #48.

HighVista Strategies first reported a position in VRDN in Q1 2022 and has held it in 18 quarters since. The position peaked at $11.6M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • HighVista Strategies held 159,885 shares of Viridian Therapeutics worth $2.94M as of Q2 2026.
  • HighVista Strategies bought 25,656 Viridian Therapeutics shares in Q2 2026, an estimated $413K.
  • Viridian Therapeutics made up 0.67% of HighVista Strategies's portfolio in Q2 2026, its #48 holding.
  • HighVista Strategies first reported a position in Viridian Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • HighVista Strategies's Viridian Therapeutics position peaked at $11.6M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.